Haemonetics Corporation (HAE)

Haemonetics Corporation remains a high-quality blood-management franchise with strong TEG and plasma software moats, but recent growth has paused due to portfolio shifts and competition. Q1 FY2026 res...

Evaluate Haemonetics' (HAE) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.

Haemonetics Corporation (NYSE:HAE ) Q1 2026 Earnings Conference Call August 7, 2025 8:00 AM ET Company Participants Christopher A. Simon - CEO, President & Director James C.

Haemonetics Corp HAE reported upbeat earnings for the first quarter on Thursday.

While the top- and bottom-line numbers for Haemonetics (HAE) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare...

Haemonetics (HAE) came out with quarterly earnings of $1.1 per share, beating the Zacks Consensus Estimate of $1.01 per share. This compares to earnings of $1.02 per share a year ago.

Beyond analysts' top-and-bottom-line estimates for Haemonetics (HAE), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quart...

Haemonetics (HAE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Pharvaris is advancing deucrictibant, an oral bradykinin B2-receptor antagonist, in two late-stage trials for hereditary angioedema patient populations. Key catalysts include RAPIDe-3 phase 3 topline ...

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that positive results from the Phase 3 OASISplus prospective switch study of donidalorsen in patients with...